ImmuneWalk Therapeutics Inc.
June 16, 2025
Company Presentation
Immunology
ImmuneWalk Therapeutics is clinical-Stage company developing therapies for I&I. Our main program is based on the discovery of a novel adhesion checkpoint, that controls the ability of certain immune cells to reach inflamed tissues. Our lead clinical-stage drug candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes and neutrophils from traveling to inflammatory tissues. Following demonstration of disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non-Alcoholic Steatohepatitis, IW-601 is currently being studied in a Phase 1 clinical trial, whose Single Ascending Dose stage l was completed successfully. Multiple catalysts are expected in 2025-2026.
Company HQ City:
Pearl River
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
IW-601
CEO
Prof Dror Harats
Year Founded
2023
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
End of Phase 1
What is your next catalyst (value inflection) update?
Oct 2025
Website
https://immunewalk.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}